Implementation and Evaluation of an Electronic Alert to Encourage Targeted Screening for HIV Infection at Foch Hospital According to Socio-demographic Criteria
NCT ID: NCT03991767
Last Updated: 2020-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
297 participants
INTERVENTIONAL
2018-04-04
2019-10-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our hypothesis is that an electronic alert would identify people who are unaware of their HIV status. This alert would be based on two data: social data (French health coverage) and the country of birth. This alert is only relevant in high-prevalence regions, as is the case in the Ile de France region.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does the Implementation of Nurse-driven HIV Screening for Key Populations in the Emergency Departments Limit Undiagnosed Infections in the Paris Metropolitan Area? DEPIST Trial (ANRS 14055)
NCT04298801
Screening Strategy for Asymptomatic Sexually Transmitted Infections (STI) in a Cohort of HIV Outpatients Men Who Have Sex With Men (DRIVER)
NCT02413632
Life Experience of People Aged 60 and Over Living with HIV
NCT05083273
Prevention, Access to Rights, Catch-up Vaccination, Treatment of Conditions During Pregnancy and for Children
NCT05085717
User-friendly HIV Testing and Counseling Services
NCT04585165
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
period 1
Period 1: Retrospective period:
Collection of data from the 12 months preceding the start of the research of hospitalized patients:
* number of hospitalizations,
* number of HIV serologies performed,
* number of patients with socio-demographic criteria justifying HIV screening.
Start of research: Implementation of the "POP-UP" electronic alert
Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.
Six possibility to answer:
1. Patient accept to participate: patient is include and receive HIV serology during their hospitalization.
2. Not time to answer to the alert
3. Patient already has a serology less than 3 months old
4. Patient followed for a known HIV infection.
5. Patient who refused the test
6. Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization.
"POP-UP" electronic alert
Implementation of the "POP-UP" electronic alert for all patients with eligibility criteria
Serology HIV
Realization of HIV serology for included patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"POP-UP" electronic alert
Implementation of the "POP-UP" electronic alert for all patients with eligibility criteria
Serology HIV
Realization of HIV serology for included patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with AME or CMU and/or CMUc, or patient born in one of the following countries/regions: Sub-Saharan Africa, Haiti, South America, Asia, Eastern Europe, Guadeloupe, Martinique and Guyana
Exclusion Criteria
* Patient being followed for a known HIV infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hopital Foch
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Zucman, MD
Role: STUDY_DIRECTOR
FOCH Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Foch
Suresnes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016/51
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.